|
|
|
Volumn 7, Issue 1, 2005, Pages 85-93
|
|
Technology evaluation: SB-485232, GlaxoSmithKline
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GAMMA INTERFERON;
IBOCTADEKIN;
RECOMBINANT INTERLEUKIN 18;
RECOMBINANT INTERLEUKIN 2;
ACUTE KIDNEY TUBULE NECROSIS;
ANEMIA;
ANTIGEN PRESENTING CELL;
ANTINEOPLASTIC ACTIVITY;
BONE METASTASIS;
CANCER IMMUNOTHERAPY;
CANCER MODEL;
CELL PROLIFERATION;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ERUPTION;
DRUG FORMULARY;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG METABOLISM;
DRUG MIXTURE;
DRUG PROTEIN BINDING;
DRUG RECEPTOR BINDING;
DRUG TARGETING;
FEMALE;
FEVER;
HUMAN;
HYPOALBUMINEMIA;
HYPOCALCEMIA;
HYPOTENSION;
IMMUNOSTIMULATION;
KIDNEY CARCINOMA;
LEUKOPENIA;
LYMPHOCYTOPENIA;
LYMPHOID HYPERPLASIA;
MALE;
MELANOMA;
METASTASIS INHIBITION;
MYALGIA;
NEUTROPENIA;
NONHUMAN;
PHASE 2 CLINICAL TRIAL;
PROTEIN FUNCTION;
REVIEW;
STRUCTURE ACTIVITY RELATION;
THROMBOCYTOPENIA;
ADJUVANTS, IMMUNOLOGIC;
ANIMALS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
HUMANS;
INTERLEUKIN-18;
MICE;
NEOPLASMS;
RECOMBINANT PROTEINS;
|
|
EID: 14244263220
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (12)
|
|
References (0)
|
